What is HC Wainwright’s Forecast for ENLV FY2025 Earnings?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Equities researchers at HC Wainwright issued their FY2025 earnings estimates for shares of Enlivex Therapeutics in a research note issued to investors on Monday, January 12th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.21) for the year. HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q4 2025 earnings at ($0.03) EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.05) EPS.

ENLV has been the topic of a number of other reports. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. D Boral Capital cut shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Finally, Wall Street Zen downgraded shares of Enlivex Therapeutics to a “strong sell” rating in a research report on Saturday, December 27th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.00.

Enlivex Therapeutics Price Performance

Shares of NASDAQ:ENLV opened at $0.93 on Wednesday. Enlivex Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.10. The company has a market capitalization of $221.67 million, a PE ratio of -1.70 and a beta of 1.52. The business has a fifty day moving average price of $0.91 and a two-hundred day moving average price of $1.08.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors have recently added to or reduced their stakes in ENLV. Citizens Financial Group Inc. RI bought a new position in Enlivex Therapeutics during the third quarter worth about $241,000. Jane Street Group LLC lifted its stake in shares of Enlivex Therapeutics by 527.4% during the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in Enlivex Therapeutics in the 3rd quarter worth approximately $57,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics News Summary

Here are the key news stories impacting Enlivex Therapeutics this week:

• Positive Sentiment: MSN reports an analyst-driven price target increase of 85.71% to $13.26, a sizable upside vs. the current stock price that can attract momentum and speculative buying. Enlivex Therapeutics (ENLV) price target increased by 85.71% to 13.26
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $13.00 target and published quarterly and FY2026 EPS estimates showing smaller per-quarter losses (generally ($0.01) per quarter in 2026 and FY2026 EPS of ($0.05)), signaling analyst conviction that losses will narrow—this supports the higher price targets and may drive longer-term investor interest. MarketBeat: ENLV analyst coverage and estimates
• Neutral Sentiment: Despite positive analyst signals, consensus still shows material negative earnings (current full-year consensus ~($0.70) EPS) and the stock is highly speculative; consider that upside is driven more by expectation of future pipeline/operational progress than by current fundamentals.
• Neutral Sentiment: Trading volume is elevated versus average, indicating heightened market attention — this can amplify moves in either direction and increase short-term volatility for ENLV.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.